Sera Prognostics (SERA) Cash from Financing Activities (2020 - 2026)
Sera Prognostics (SERA) posted Cash from Financing Activities of $20000.0 for Q1 2026, down 78.49% on a QoQ basis from $93000.0 in Q4 2025, and down 99.96% year-over-year from $53.5 million in Q1 2025.
Sera Prognostics (SERA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Sera Prognostics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $20000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 99.96% year-over-year to $20000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $504000.0 (down 99.09% YoY) and the FY2025 annual result came in at $54.0 million, up 1970.76% from the prior year.
- Cash from Financing Activities was $20000.0 for Q1 2026 at Sera Prognostics, down from $93000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $53.5 million in Q1 2025 and bottomed at -$116000.0 in Q4 2022.
- A 5-year average of $3.4 million and a median of $117000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 413.51% — and 2025, when it surged 4979.89%.
- Sera Prognostics' Cash from Financing Activities stood at -$116000.0 in 2022, then jumped by 631.03% to $616000.0 in 2023, then slumped by 62.01% to $234000.0 in 2024, then slumped by 60.26% to $93000.0 in 2025, then plunged by 78.49% to $20000.0 in 2026.
- Business Quant data shows SERA's Cash from Financing Activities at $20000.0 in Q1 2026, $93000.0 in Q4 2025, and $373000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -25.00 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 21.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -26.93 Mn |
| 10 | Sera Prognostics | 105.54 Mn | 105.54 Mn | -28,000.00 | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20,000.00 |
| Mar 31, 2026 | 20,000.00 |
| Dec 31, 2025 | 93,000.00 |
| Dec 31, 2025 | 93,000.00 |
| Sep 30, 2025 | 373,000.00 |
| Sep 30, 2025 | 373,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Mar 31, 2025 | 53.54 Mn |
| Mar 31, 2025 | 53.54 Mn |
| Dec 31, 2024 | 234,000.00 |
| Dec 31, 2024 | 234,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.05 Mn |
| Mar 31, 2024 | 1.05 Mn |
| Dec 31, 2023 | 616,000.00 |
| Dec 31, 2023 | 616,000.00 |